Cargando…

Hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patients

Prostate cancer is a significant public health burden and one of the most common cancers globally and in the United States. The current cornerstone of prostate cancer systemic treatment involves the suppression of androgen receptor (AR) signaling, either by reducing the body’s testosterone productio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lyou, Yung, Dorff, Tanya B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article on Current and Future Topics on Prostate Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350226/ https://www.ncbi.nlm.nih.gov/pubmed/34430422 http://dx.doi.org/10.21037/tau-20-1053

Ejemplares similares

HbA1c Variability and Cardiovascular Events in Patients with Prostate Cancer Receiving Androgen Deprivation Therapy
por: Chan, Jeffrey Shi Kai, et al.
Publicado: (2022)

Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes
por: Ben-Salem, Salma, et al.
Publicado: (2020)

Narrative review of management strategies and outcomes in node-positive prostate cancer
por: D’Rummo, Kevin A., et al.
Publicado: (2021)

Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review
por: de Kouchkovsky, Ivan, et al.
Publicado: (2021)

Focal therapy for primary and salvage prostate cancer treatment: a narrative review
por: Tracey, Andrew T., et al.
Publicado: (2021)

Profiling of Skeletal Muscle and Adipose Tissue Depots in Men with Advanced Prostate Cancer Receiving Different Forms of Androgen Deprivation Therapy
por: Blow, Tahj A., et al.
Publicado: (2023)

A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy
por: Kasparian, Saro, et al.
Publicado: (2023)

MRI/PET Imaging in elevated PSA and localized prostate cancer: a narrative review
por: Regmi, Subodh K., et al.
Publicado: (2021)

Oligometastatic prostate cancer: definition and the role of local and systemic therapy: a narrative review
por: Mahjoub, Samy, et al.
Publicado: (2021)

Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study
por: Zimmerman, Yvette, et al.
Publicado: (2022)

Preface to “Current and Future Topics on Prostate Cancer”
por: Konety, Badrinath R., et al.
Publicado: (2021)

Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer—a narrative review
por: Sagaram, Smitha, et al.
Publicado: (2021)

A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study
por: Barrett, Tristan, et al.
Publicado: (2022)

Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)
por: Coelingh Bennink, Herjan J.T., et al.
Publicado: (2021)

Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam
por: Hogenhout, Renée, et al.
Publicado: (2022)

Characteristics of Patients in SPCG-15—A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer
por: Gongora, Magdalena, et al.
Publicado: (2022)

A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2021)

Erratum to hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patients
Publicado: (2021)

Epigenetics in prostate cancer: clinical implications
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Side-specific, Microultrasound-based Nomogram for the Prediction of Extracapsular Extension in Prostate Cancer
por: Pedraza, Adriana M., et al.
Publicado: (2022)

Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy
por: Rajan, Prabhakar, et al.
Publicado: (2014)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
por: Lendorf, Maria Elisabeth, et al.
Publicado: (2021)

Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions
por: Eyrich, Nicholas W., et al.
Publicado: (2021)

Every urologist and oncologist should know about treating sexual and gender minority prostate cancer patients: translating research findings into clinical practice
por: Rosser, B. R. Simon, et al.
Publicado: (2021)

Subtotal surgical therapy for localized prostate cancer: a single-center precision prostatectomy experience in 25 patients, and SEER-registry data analysis
por: Sood, Akshay, et al.
Publicado: (2021)

Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
por: Ali Shah, Syed Imran
Publicado: (2015)

Androgen receptor signaling–mitochondrial DNA–oxidative phosphorylation: A critical triangle in early prostate cancer
por: Sakellakis, Minas, et al.
Publicado: (2022)

Can androgen-deprivation therapy obviate the need of channel transurethral resection of the prostate in advanced prostate cancer with urinary retention? A prospective study
por: Sood, Rajeev, et al.
Publicado: (2017)

Magnetic Resonance Imaging–targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer
por: Alkema, Nicolette G., et al.
Publicado: (2022)

Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study)
por: Woo, Henry H., et al.
Publicado: (2022)

Defining Prostatic Vascular Pedicle Recurrence and the Anatomy of Local Recurrence of Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography
por: Dundee, Philip, et al.
Publicado: (2022)

Prostate Cancer Risk Inflation as a Consequence of Image-targeted Biopsy of the Prostate: A Computer Simulation Study
por: Robertson, Nicola L., et al.
Publicado: (2014)

Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer
por: Wagaskar, Vinayak G., et al.
Publicado: (2021)

Prostate Cancer Tumor Volume and Genomic Risk
por: Ramaswamy, Ashwin, et al.
Publicado: (2023)

Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study
por: Norris, Joseph M., et al.
Publicado: (2021)

A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy
por: Kelly, Brian D., et al.
Publicado: (2023)

The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator
por: Parekh, Sneha, et al.
Publicado: (2022)

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
por: Bjartell, Anders, et al.
Publicado: (2022)

External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort
por: Chandra Engel, Jan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g9ftnj7d71321mfbegu2l36c71